Patients asking about statins and memory often bring two concerns to the same appointment. They may have read that cholesterol treatment could protect against Alzheimer’s, while also hearing that statins can cause forgetfulness. For someone with a family history of dementia, either claim can carry considerable weight.

These questions require different kinds of evidence. Whether a medication reduces heart attacks or ischemic strokes is separate from whether it prevents Alzheimer’s disease, and both differ from the question of whether an individual might experience a side effect. Keeping those distinctions clear makes the discussion more useful and helps avoid treatment decisions based on an incomplete account of the research.

What Observational Studies Have Found

Much of the interest in statins and dementia comes from studies that follow people receiving care rather than randomly assigning treatment. These studies can include large populations and years of medical records, allowing researchers to examine associations that would be difficult to study in a short clinical trial.

A 2025 study published in the Journal of Neurology, Neurosurgery & Psychiatry examined LDL cholesterol levels, statin use, and subsequent dementia diagnoses using data from multiple hospitals in South Korea. Lower LDL cholesterol was associated with lower dementia risk, and statin use was associated with an additional reduction in risk within the low-LDL group. The investigators used statistical matching to make the comparison groups more similar, but treatment was not randomly assigned.¹

The broader observational literature often points in the same direction. A 2025 systematic review combining 55 observational studies and more than seven million participants reported an association between statin use and lower dementia risk. Its size makes the finding important to investigate, but combining many observational studies does not remove the limitations inherent in their design.²

Why an Association Does Not Establish Prevention

People who take statins may differ from those who do not in ways that influence their long-term health. They may receive more consistent medical care, take blood pressure medication more reliably, or have different smoking, exercise, and dietary habits. Researchers can adjust for recorded differences, but medical records rarely capture these factors completely.

The differences can also work in the opposite direction. Statin users often begin with more cardiovascular disease or diabetes, which may increase their underlying dementia risk. Early cognitive changes can affect medication adherence and prescribing decisions before dementia is formally diagnosed. These issues complicate the interpretation of a lower dementia rate among treated patients.

This does not make observational research unhelpful. It means that an association should be interpreted as evidence that may support a hypothesis, rather than as proof that prescribing the medication will produce the same outcome.

What Randomized Trials Have Shown

Randomized trials reduce many of these biases by assigning treatment independently of a participant’s usual care or personal habits. In the trials evaluated in a 2016 Cochrane review, statins did not prevent cognitive decline or dementia. The review included two large trials with 26,340 participants.³

The PROSPER trial provides a specific example. It repeatedly assessed cognitive performance in 5,804 adults aged 70 to 82 who received pravastatin or placebo. Over approximately three years, cognitive decline did not differ between the groups.⁴

These findings do not resolve every question about treatment timing. Starting a medication in older age and following participants for several years cannot fully answer whether decades of cardiovascular risk reduction beginning in midlife might influence later dementia risk. That remains a research question, however, rather than an established reason to prescribe statins specifically for Alzheimer’s prevention.

What About Reports of Memory Loss?

Statin prescribing information acknowledges rare reports of forgetfulness, confusion, and other cognitive symptoms. The reported symptoms have generally been nonserious and reversible after treatment was stopped. Reports made after a medication reaches the market can identify possible adverse effects, but they cannot establish how frequently the drug causes a symptom or whether every reported event was caused by treatment.⁵

Randomized evidence provides a different perspective. A systematic review of randomized trials did not find significant adverse effects of statins on cognitive testing. This is reassuring at the population level, while still leaving room to evaluate an individual who notices a change after starting a prescription.⁶

A patient’s experience deserves attention even when a side effect is uncommon. The clinician can review the timing of symptoms, sleep, other medications, mood, and relevant medical conditions, then consider whether a supervised adjustment is appropriate. A report of temporary forgetfulness should not automatically be interpreted as Alzheimer’s disease, and progressive memory difficulties should not be attributed to a statin without further evaluation.

How Cardiovascular Health Fits Into the Discussion

Alzheimer’s disease and vascular cognitive impairment are different conditions, although they can coexist. A person may have Alzheimer’s pathology together with injury from strokes or disease affecting the brain’s small blood vessels. This helps explain why cardiovascular health remains relevant to cognitive aging even when a medication has not been proven to prevent Alzheimer’s.

Statins have established cardiovascular indications, including reducing the risk of heart attacks and ischemic strokes in appropriate patients. Those benefits should be assessed on their own evidence. Preventing vascular injury is clinically valuable without assuming that it also prevents the amyloid and tau pathology associated with Alzheimer’s disease.

The National Institute on Aging identifies management of cardiovascular and metabolic conditions, including high blood pressure and diabetes, as part of maintaining cognitive health. Physical activity, smoking cessation, and other healthy behaviors also deserve attention. These measures support health and may reduce dementia risk, but they cannot guarantee that an individual will remain free of cognitive disease.⁷

The HormoneSynergy® Perspective

At HormoneSynergy®, we consider lipid treatment within the person’s broader cardiovascular and metabolic assessment. That includes the standard lipid profile, blood pressure, glucose regulation, smoking history, family history, and existing vascular disease. ApoB and Lp(a) can provide additional information when appropriate, while selected imaging may help clarify a clinical decision.

These measurements answer particular questions. ApoB helps assess the burden of atherogenic lipoprotein particles; Lp(a) provides information about a largely inherited cardiovascular risk factor. Neither is a test for Alzheimer’s disease, and a favorable result does not exclude future cognitive decline.

When a statin is appropriate, the discussion should include the expected cardiovascular benefit, possible adverse effects, treatment alternatives, and the patient’s priorities. Nutrition, exercise, sleep, and metabolic care remain relevant whether medication is prescribed or not. Treatment should be reassessed when symptoms, risk, or circumstances change.

The observational findings on dementia are worth following, but they should not carry more certainty than the studies allow. For now, we can explain the established cardiovascular benefits of statins, acknowledge the reassuring cognitive safety data, and remain clear that Alzheimer’s prevention has not been demonstrated.

Frequently Asked Questions

Have statins been proven to prevent Alzheimer’s disease?

No. Observational studies often associate statin use with lower dementia risk, but randomized trials have not established statins as a treatment for preventing Alzheimer’s disease.

Why do observational studies and randomized trials differ?

Observational studies compare people whose treatment decisions may reflect differences in health, medical care, and behavior. Randomized trials reduce these biases, but their findings also depend on participants’ ages, treatment duration, and the outcomes measured.

Do statins cause dementia?

Randomized evidence has not demonstrated that statins cause dementia or consistent cognitive impairment. Rare memory complaints have been reported in prescribing information, generally described as nonserious and reversible. These reports are different from evidence of progressive dementia.

Should I start a statin solely to prevent Alzheimer’s?

Current evidence does not establish Alzheimer’s prevention as a reason to start a statin. Treatment decisions should be based on cardiovascular indications, expected benefit, potential adverse effects, and individual preferences.

What should I do if I notice memory changes while taking a statin?

Contact your prescribing clinician to review the symptoms and their timing. Evaluation can consider other medications, sleep, mood, medical conditions, and a possible treatment-related effect. Discuss any medication change with the clinician rather than stopping treatment on your own.

References and Further Reading

1. Low-density lipoprotein cholesterol levels and risk of incident dementia: a distributed network analysis using common data models. Journal of Neurology, Neurosurgery & Psychiatry. 2025. doi:10.1136/jnnp-2024-334708. Read the study.
2. Westphal Filho FL, et al. Statin use and dementia risk: A systematic review and updated meta-analysis. 2025. Read the observational evidence review.
3. McGuinness B, et al. Statins for the prevention of dementia. Cochrane Database of Systematic Reviews. 2016;CD003160. Read the review.
4. Trompet S, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. Journal of Neurology. 2010;257:85–90. Read the randomized trial findings.
5. LIPITOR® (atorvastatin calcium) prescribing information. See the section on postmarketing experience. Read the prescribing information.
6. Ott BR, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. Journal of General Internal Medicine. 2015;30:348–358. Read the review.
7. National Institute on Aging. Cognitive Health and Older Adults.

This article provides general education and does not replace individualized medical advice. Decisions about prescription medication should be made with your treating clinician.